Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab with Gemcitabine and Cisplatin in Advanced Squamous NSCLC
NCT01763788Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of necitumumab in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose Limiting Toxicities and Overall Survival up to 39 Months. Started May 2013; status: completed.
02
Drugs
necitumumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01763788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763788.